<DOC>
	<DOC>NCT00353522</DOC>
	<brief_summary>This 2 arm study will investigate the efficacy and safety of RO4607381 in patients with coronary heart disease, or CHD risk equivalent. After a pre-randomization phase of 5-12 weeks, patients will be randomized to receive either RO4607381 (900mg po) or placebo po daily for 24 weeks, with concomitant atorvastatin 10-80mg daily, and changes in cholesterol level and lipoprotein metabolism will be measured. The anticipated time on study treatment is 3-12 months, and the target sample size is 100-500 individuals.</brief_summary>
	<brief_title>A Study of RO4607381 in Patients With Coronary Heart Disease (CHD) or a CHD Risk Equivalent.</brief_title>
	<detailed_description />
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Dalcetrapib</mesh_term>
	<criteria>adult patients, 1875 years of age; CHD or CHD risk equivalent; body weight &lt;125kg at visit 1. recent (within 3 weeks of screening) clinically significant coronary events; history of statinassociated myopathy, or intolerance to statin; history of malignancy (except for curatively treated basal cell or squamous cell cancer of the skin) during the 3 years prior to screening; exposure to RO4607381 in past 12 months.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>